Brian S. Muntean
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Brian S. Muntean has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Douglas C. Sloan
Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, United States
5 shared publicationsYini Liao
Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, USA
4 shared publications- Yini Liao
Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, Georgia, USA
4 shared publications Casey E. Cryan
Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, Georgia 30912
2 shared publications- Cesare Orlandi
Department of Pharmacology and Physiology, University of Rochester Medical Center
2 shared publications - Douglas C. Sloan
Vascular Biology Center, Medical College of Georgia, Augusta University, 1460 Laney Walker Blvd., Augusta, GA 30912, USA
2 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Gαo/z-biased coupling profile of the dopamine D3 receptor
Dopamine receptors are G protein coupled receptors (GPCRs) that serve as key targets for FDA-approved drugs to treat various neuropsychiatric disorders. Notably, ~11% of all marketed GPCR-targeting drugs act on dopamine receptors. Five GPCRs mediate the effects of endogenous dopamine and compounds used to treat Parkinson’s disease, schizophrenia, and other conditions. However, on-target side effects associated with these medications highlight the need to analyze dopamine receptor signaling to design safer, more effective therapeutics. Here, we characterize the G protein coupling of dopamine D2-like receptors and observe the striking inability of D3R to engage with Gαi proteins while effectively activating Gαo/z subtypes. Applying orthogonal cell-based assays with wild-type G proteins in parental and ΔGαi/o/z cells, we conclusively establish that D3R does not activate Gαi proteins. Further analysis of Gαi2:GαoA and D2R:D3R chimeras reveals that this selective inability is driven by molecular determinants located within the α5 helix of Gαi and ICL2 of D3R. Guided by cryo-EM structures, we model the interface between these regions to clarify the structural basis of selectivity. Finally, treating hippocampal neurons in acute slices with selective agonists and antagonists reveals marked differences in their regulation of endogenous adenylyl cyclase and cAMP, underscoring the neurophysiological significance of our findings.
- 29 June 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessGαo/z-biased coupling profile of the dopamine D3 receptor
Dopamine receptors are G protein coupled receptors (GPCRs) that serve as key targets for FDA-approved drugs to treat various neuropsychiatric disorders. Notably, ~11% of all marketed GPCR-targeting drugs act on dopamine receptors. Five GPCRs mediate the effects of endogenous dopamine and compounds used to treat Parkinson’s disease, schizophrenia, and other conditions. However, on-target side effects associated with these medications highlight the need to analyze dopamine receptor signaling to design safer, more effective therapeutics. Here, we characterize the G protein coupling of dopamine D2-like receptors and observe the striking inability of D3R to engage with Gαi proteins while effectively activating Gαo/z subtypes. Applying orthogonal cell-based assays with wild-type G proteins in parental and ΔGαi/o/z cells, we conclusively establish that D3R does not activate Gαi proteins. Further analysis of Gαi2:GαoA and D2R:D3R chimeras reveals that this selective inability is driven by molecular determinants located within the α5 helix of Gαi and ICL2 of D3R. Guided by cryo-EM structures, we model the interface between these regions to clarify the structural basis of selectivity. Finally, treating hippocampal neurons in acute slices with selective agonists and antagonists reveals marked differences in their regulation of endogenous adenylyl cyclase and cAMP, underscoring the neurophysiological significance of our findings.
- Open Access
- 12 October 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (12) , 110813
Pathogenic variants in KCTD1 disrupt cAMP signaling and cellular communication associated with developmental pathways
- 12 October 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (12) , 110813
Open AccessPathogenic variants in KCTD1 disrupt cAMP signaling and cellular communication associated with developmental pathways
- Open Access
- 1 October 2025
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 13, 1642190
Comprehensive medicinal chemistry survey highlights a portfolio of lead molecules for Alzheimer’s disease therapy
The World Health Organization reports 10 million new patients with dementia each year. The most common form of dementia is Alzheimer’s disease (AD), which constitutes up to 70% of cases. AD is mainly characterized by loss of memory, which, in addition to its debilitating individual effect, represents a burden of 1.3 trillion US dollars globally. The staggering scale of hardship has spurred intense investigations from the scientific community in search of therapeutic solutions. Recent advances to combat AD involve the identification of numerous neural targets and concomitant chemical interventions as nodes of therapy. Due to disparate biological and chemical facets of AD therapy, a comprehensive perspective covering both arenas is currently missing from the literature. This perspective aims to provide an extensive understanding of anti-AD mechanics alongside small-molecule drug design efforts from a medicinal chemist viewpoint. We are confident that this survey of the literature will provide a resourceful motivation to propel future research efforts towards successful Alzheimer’s disease therapy.
- 1 October 2025
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 13, 1642190
Open AccessComprehensive medicinal chemistry survey highlights a portfolio of lead molecules for Alzheimer’s disease therapy
The World Health Organization reports 10 million new patients with dementia each year. The most common form of dementia is Alzheimer’s disease (AD), which constitutes up to 70% of cases. AD is mainly characterized by loss of memory, which, in addition to its debilitating individual effect, represents a burden of 1.3 trillion US dollars globally. The staggering scale of hardship has spurred intense investigations from the scientific community in search of therapeutic solutions. Recent advances to combat AD involve the identification of numerous neural targets and concomitant chemical interventions as nodes of therapy. Due to disparate biological and chemical facets of AD therapy, a comprehensive perspective covering both arenas is currently missing from the literature. This perspective aims to provide an extensive understanding of anti-AD mechanics alongside small-molecule drug design efforts from a medicinal chemist viewpoint. We are confident that this survey of the literature will provide a resourceful motivation to propel future research efforts towards successful Alzheimer’s disease therapy.
- Open Access
Go/z-biased coupling profile of the dopamine D3 receptor
Dopamine receptors are G protein coupled receptors (GPCRs) that serve as key targets for FDA-approved drugs used to treat various neuropsychiatric disorders. Notably, ∼11% of all marketed GPCR-targeting drugs act on dopamine receptors. Five GPCRs mediate the effects of endogenous dopamine and compounds used to treat Parkinson’s disease, schizophrenia, and other conditions. However, on-target side effects associated with these medications highlight the need to analyze dopamine receptor signaling to design safer, more effective therapeutics. We characterized the G protein coupling of dopamine D2-like receptors and observed the striking inability of D3R to engage with G i proteins while effectively activating G o and G z subtypes. Applying orthogonal cell-based assays that utilize wild-type G proteins both in parental and ΔGα i/o/z cells, we conclusively established that D3R does not activate G i proteins. Further analysis of Gα i2 :Gα oA and D2R:D3R chimeras revealed that this selective inability is driven by molecular determinants located within the α5 helix of Gα i and the intracellular loop 2 (ICL2) of D3R. Guided by cryo-EM structures, we modeled the interface between these regions to better understand the structural basis of this selectivity. Finally, we treated hippocampal neurons in acute brain slices with selective agonists for D2R and D3R and observed marked differences in their ability to regulate endogenous adenylyl cyclase to produce cAMP, highlighting the neurophysiological significance of our findings.
Open AccessGo/z-biased coupling profile of the dopamine D3 receptor
Dopamine receptors are G protein coupled receptors (GPCRs) that serve as key targets for FDA-approved drugs used to treat various neuropsychiatric disorders. Notably, ∼11% of all marketed GPCR-targeting drugs act on dopamine receptors. Five GPCRs mediate the effects of endogenous dopamine and compounds used to treat Parkinson’s disease, schizophrenia, and other conditions. However, on-target side effects associated with these medications highlight the need to analyze dopamine receptor signaling to design safer, more effective therapeutics. We characterized the G protein coupling of dopamine D2-like receptors and observed the striking inability of D3R to engage with G i proteins while effectively activating G o and G z subtypes. Applying orthogonal cell-based assays that utilize wild-type G proteins both in parental and ΔGα i/o/z cells, we conclusively established that D3R does not activate G i proteins. Further analysis of Gα i2 :Gα oA and D2R:D3R chimeras revealed that this selective inability is driven by molecular determinants located within the α5 helix of Gα i and the intracellular loop 2 (ICL2) of D3R. Guided by cryo-EM structures, we modeled the interface between these regions to better understand the structural basis of this selectivity. Finally, we treated hippocampal neurons in acute brain slices with selective agonists for D2R and D3R and observed marked differences in their ability to regulate endogenous adenylyl cyclase to produce cAMP, highlighting the neurophysiological significance of our findings.
- 10 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6756) , 200-206
Discrete spatiotemporal encoding of striatal dopamine transmission
Dopamine (DA) transmission critically regulates diverse, basal ganglia–dependent behaviors by activating distinct subtypes of G protein–coupled receptors. Spatially broad DA release has been extensively characterized, but how DA transmission affects striatal function at a subcellular scale remains poorly understood. Using 2P imaging and whole-cell electrophysiology, we defined the spatiotemporal properties of DA transmission onto striatal indirect pathway spiny projection neurons. Sparse activation of DA release sites evoked localized DA signals, producing spatially discrete, D2 receptor–mediated responses across dendrites. The spatiotemporal properties of DA receptor signaling differed between downstream intracellular pathways. We propose that membrane-delimited Gβγ signaling occurs in parallel to intracellular second messenger pathways, but on different spatial and temporal scales, providing a mechanism for precise decoding of DA signals by striatal neurons.
- 10 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6756) , 200-206
Discrete spatiotemporal encoding of striatal dopamine transmission
Dopamine (DA) transmission critically regulates diverse, basal ganglia–dependent behaviors by activating distinct subtypes of G protein–coupled receptors. Spatially broad DA release has been extensively characterized, but how DA transmission affects striatal function at a subcellular scale remains poorly understood. Using 2P imaging and whole-cell electrophysiology, we defined the spatiotemporal properties of DA transmission onto striatal indirect pathway spiny projection neurons. Sparse activation of DA release sites evoked localized DA signals, producing spatially discrete, D2 receptor–mediated responses across dendrites. The spatiotemporal properties of DA receptor signaling differed between downstream intracellular pathways. We propose that membrane-delimited Gβγ signaling occurs in parallel to intracellular second messenger pathways, but on different spatial and temporal scales, providing a mechanism for precise decoding of DA signals by striatal neurons.
- Open Access
- 5 June 2025
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 45 (28)
Bmal1 Modulates Striatal cAMP Signaling and Motor Learning
The circadian rhythm shapes behavioral processes by providing temporal cues for molecular regulation and adaptation in the hypothalamus of the brain. Deeper yet in the striatum of the brain, circadian rhythm also exerts an impact, conditioning diurnal patterns in neurodegenerative-related motor dysfunction. While motor properties are clearly linked to striatal dopamine, the interplay between the circadian rhythm with the key circadian transcription factor Bmal1 and dopamine signal decoding remains unknown. Here, we utilized both sexes of global and local striatal Bmal1 knock-out mice to investigate changes in dopamine-mediated cAMP signaling and motor behavior. By conducting a 24 h time-course study, we first established Bmal1-dependent molecular signatures in striatal dopamine signaling machinery that correlated with cAMP levels. Next, recording real-time signal transduction with a two-photon FRET biosensor in brain slices revealed diminished efficacy of dopamine signaling in the absence of Bmal1. As a final functional outcome, we then found that striatal Bmal1 was necessary for motor learning in mice. Altogether, our data support a strong connection between striatal Bmal1 and dopamine signaling with potential impact in brain-related motor function.
- 5 June 2025
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 45 (28)
Open AccessBmal1 Modulates Striatal cAMP Signaling and Motor Learning
The circadian rhythm shapes behavioral processes by providing temporal cues for molecular regulation and adaptation in the hypothalamus of the brain. Deeper yet in the striatum of the brain, circadian rhythm also exerts an impact, conditioning diurnal patterns in neurodegenerative-related motor dysfunction. While motor properties are clearly linked to striatal dopamine, the interplay between the circadian rhythm with the key circadian transcription factor Bmal1 and dopamine signal decoding remains unknown. Here, we utilized both sexes of global and local striatal Bmal1 knock-out mice to investigate changes in dopamine-mediated cAMP signaling and motor behavior. By conducting a 24 h time-course study, we first established Bmal1-dependent molecular signatures in striatal dopamine signaling machinery that correlated with cAMP levels. Next, recording real-time signal transduction with a two-photon FRET biosensor in brain slices revealed diminished efficacy of dopamine signaling in the absence of Bmal1. As a final functional outcome, we then found that striatal Bmal1 was necessary for motor learning in mice. Altogether, our data support a strong connection between striatal Bmal1 and dopamine signaling with potential impact in brain-related motor function.
- Open Access
- 15 April 2025
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 23 (4) , e3003117
The G protein modifier KCTD5 tunes the decoding of neuromodulatory signals necessary for motor function in striatal neurons
G proteins (Gα and Gβγ subtypes) drive adenylyl cyclase type 5 (AC5) synthesis of cAMP in striatal neurons, which is essential for motor coordination. KCTD5 directly interacts with Gβγ to delimit signaling events, yet downstream impact of KCTD5 in striatal circuits is not known. Here, generation of a conditional Kctd5 knockout mouse identified that loss of striatal KCTD5 leads to a dystonic phenotype, coordination deficits, and skewed transitions between behavioral syllables. 2-photon imaging of a cAMP biosensor revealed electrically evoked dopaminergic responses were significantly augmented in the absence of KCTD5 in striatal circuits. cAMP sensitization was rescued in situ by expression of a Gβγ-scavenging nanobody and motor deficits were partially rescued in vivo by pharmacological antagonism of the indirect striatal cAMP pathway. Therefore, KCTD5 acts as a brake on cAMP signaling in striatal neurons important for tuning dopaminergic signaling and motor coordination.
- 15 April 2025
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 23 (4) , e3003117
Open AccessThe G protein modifier KCTD5 tunes the decoding of neuromodulatory signals necessary for motor function in striatal neurons
G proteins (Gα and Gβγ subtypes) drive adenylyl cyclase type 5 (AC5) synthesis of cAMP in striatal neurons, which is essential for motor coordination. KCTD5 directly interacts with Gβγ to delimit signaling events, yet downstream impact of KCTD5 in striatal circuits is not known. Here, generation of a conditional Kctd5 knockout mouse identified that loss of striatal KCTD5 leads to a dystonic phenotype, coordination deficits, and skewed transitions between behavioral syllables. 2-photon imaging of a cAMP biosensor revealed electrically evoked dopaminergic responses were significantly augmented in the absence of KCTD5 in striatal circuits. cAMP sensitization was rescued in situ by expression of a Gβγ-scavenging nanobody and motor deficits were partially rescued in vivo by pharmacological antagonism of the indirect striatal cAMP pathway. Therefore, KCTD5 acts as a brake on cAMP signaling in striatal neurons important for tuning dopaminergic signaling and motor coordination.
- Open Access
- 16 October 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (43)
KCTD1 regulation of Adenylyl cyclase type 5 adjusts striatal cAMP signaling
Dopamine transfers information to striatal neurons, and disrupted neurotransmission leads to motor deficits observed in movement disorders. Striatal dopamine converges downstream to Adenylyl Cyclase Type 5 (AC5)-mediated synthesis of cAMP, indicating the essential role of signal transduction in motor physiology. However, the relationship between dopamine decoding and AC5 regulation is unknown. Here, we utilized an unbiased global protein stability screen to identify Potassium Channel Tetramerization Domain 1 (KCTD1) as a key regulator of AC5 level that is mechanistically tied to N-linked glycosylation. We then implemented a CRISPR/SaCas9 approach to eliminate KCTD1 in striatal neurons expressing a Förster resonance energy transfer (FRET)-based cAMP biosensor. 2-photon imaging of striatal neurons in intact circuits uncovered that dopaminergic signaling was substantially compromised in the absence of KCTD1. Finally, knockdown of KCTD1 in genetically defined dorsal striatal neurons significantly altered motor behavior in mice. These results reveal that KCTD1 acts as an essential modifier of dopaminergic signaling by stabilizing striatal AC5.
- 16 October 2024
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (43)
Open AccessKCTD1 regulation of Adenylyl cyclase type 5 adjusts striatal cAMP signaling
Dopamine transfers information to striatal neurons, and disrupted neurotransmission leads to motor deficits observed in movement disorders. Striatal dopamine converges downstream to Adenylyl Cyclase Type 5 (AC5)-mediated synthesis of cAMP, indicating the essential role of signal transduction in motor physiology. However, the relationship between dopamine decoding and AC5 regulation is unknown. Here, we utilized an unbiased global protein stability screen to identify Potassium Channel Tetramerization Domain 1 (KCTD1) as a key regulator of AC5 level that is mechanistically tied to N-linked glycosylation. We then implemented a CRISPR/SaCas9 approach to eliminate KCTD1 in striatal neurons expressing a Förster resonance energy transfer (FRET)-based cAMP biosensor. 2-photon imaging of striatal neurons in intact circuits uncovered that dopaminergic signaling was substantially compromised in the absence of KCTD1. Finally, knockdown of KCTD1 in genetically defined dorsal striatal neurons significantly altered motor behavior in mice. These results reveal that KCTD1 acts as an essential modifier of dopaminergic signaling by stabilizing striatal AC5.
- Open Access
- 20 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 14317
KCTD5 Forms Hetero-Oligomeric Complexes with Various Members of the KCTD Protein Family
Potassium Channel Tetramerization Domain 5 (KCTD5) regulates diverse aspects of physiology, ranging from neuronal signaling to colorectal cancer. A key feature of KCTD5 is its self-assembly into multi-subunit oligomers that seemingly enables participation in an array of protein–protein interactions. KCTD5 has recently been reported to form hetero-oligomeric complexes with two similar KCTDs (KCTD2 and KCTD17). However, it is not known if KCTD5 forms hetero-oligomeric complexes with the remaining KCTD protein family which contains over two dozen members. Here, we demonstrate that KCTD5 interacts with various KCTD proteins when assayed through co-immunoprecipitation in lysed cells. We reinforced this dataset by examining KCTD5 interactions in a live-cell bioluminescence resonance energy transfer (BRET)-based approach. Finally, we developed an IP-luminescence approach to map regions on KCTD5 required for interaction with a selection of KCTD that have established roles in neuronal signaling. We report that different regions on KCTD5 are responsible for uniquely contributing to interactions with other KCTD proteins. While our results help unravel additional interaction partners for KCTD5, they also reveal additional complexities in KCTDs’ biology. Moreover, our findings also suggest that KCTD hetero-oligomeric interactions may occur throughout the KCTD family.
- 20 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (18) , 14317
Open AccessKCTD5 Forms Hetero-Oligomeric Complexes with Various Members of the KCTD Protein Family
Potassium Channel Tetramerization Domain 5 (KCTD5) regulates diverse aspects of physiology, ranging from neuronal signaling to colorectal cancer. A key feature of KCTD5 is its self-assembly into multi-subunit oligomers that seemingly enables participation in an array of protein–protein interactions. KCTD5 has recently been reported to form hetero-oligomeric complexes with two similar KCTDs (KCTD2 and KCTD17). However, it is not known if KCTD5 forms hetero-oligomeric complexes with the remaining KCTD protein family which contains over two dozen members. Here, we demonstrate that KCTD5 interacts with various KCTD proteins when assayed through co-immunoprecipitation in lysed cells. We reinforced this dataset by examining KCTD5 interactions in a live-cell bioluminescence resonance energy transfer (BRET)-based approach. Finally, we developed an IP-luminescence approach to map regions on KCTD5 required for interaction with a selection of KCTD that have established roles in neuronal signaling. We report that different regions on KCTD5 are responsible for uniquely contributing to interactions with other KCTD proteins. While our results help unravel additional interaction partners for KCTD5, they also reveal additional complexities in KCTDs’ biology. Moreover, our findings also suggest that KCTD hetero-oligomeric interactions may occur throughout the KCTD family.
- Open Access
- 6 September 2023
- Published by Society for Neuroscience in eneuro
- Vol. 10 (9)
Customizable Open-Source Rotating Rod (Rotarod) Enables Robust Low-Cost Assessment of Motor Performance in Mice
Reliable measurements of motor learning and coordination in mice are fundamental aspects of neuroscience research. Despite the advent of deep-learning approaches for motor assessment, performance testing on a rotating rod (rotarod) has remained a staple in the neuroscientist’s toolbox. Surprisingly, commercially available rotarod instruments offer limited experimental flexibility at a relatively high cost. In order to address these concerns, we engineered a highly-customizable, low-budget rotarod device with increased functionality. Here, we present a detailed guide to assemble this rotarod using simple materials. Our apparatus incorporates a variation of interchangeable rod sizes and designs which provides for adjustable testing sensitivity. Moreover, our rotarod is driven by open-source software enabling bespoke acceleration ramps and sequences. Finally, we report the strengths and weaknesses of each rod design following multiday testing on cohorts of C57BL/6 mice. We expect explorations in deviant rod types to provide a foundation for the development of increasingly sensitive models for motor performance testing along with low-budget alternatives for the research community.
- 6 September 2023
- Published by Society for Neuroscience in eneuro
- Vol. 10 (9)
Open AccessCustomizable Open-Source Rotating Rod (Rotarod) Enables Robust Low-Cost Assessment of Motor Performance in Mice
Reliable measurements of motor learning and coordination in mice are fundamental aspects of neuroscience research. Despite the advent of deep-learning approaches for motor assessment, performance testing on a rotating rod (rotarod) has remained a staple in the neuroscientist’s toolbox. Surprisingly, commercially available rotarod instruments offer limited experimental flexibility at a relatively high cost. In order to address these concerns, we engineered a highly-customizable, low-budget rotarod device with increased functionality. Here, we present a detailed guide to assemble this rotarod using simple materials. Our apparatus incorporates a variation of interchangeable rod sizes and designs which provides for adjustable testing sensitivity. Moreover, our rotarod is driven by open-source software enabling bespoke acceleration ramps and sequences. Finally, we report the strengths and weaknesses of each rod design following multiday testing on cohorts of C57BL/6 mice. We expect explorations in deviant rod types to provide a foundation for the development of increasingly sensitive models for motor performance testing along with low-budget alternatives for the research community.